February 2, 2026: FDA Posts Updated Safety Label for Mounjaro On January 20, 2026, the FDA posted an updated safety/warning label with new patient information for those taking Mounjaro (tirzepatide)
The biology of GLP-1 cells has garnered renewed interest due to the current approval of GLP-1 analogs for the pharmacological treatment of type-2 diabetes and obesity 13,14,15
It can also make the skin produce more sebum, which in turn clogs pores and develops acne
27 found milder symptoms and histopathologic severity to DSS-induced colitis in H4R / BALB/c mice compared with wild-type (WT) mice or in WT mice undergoing constant pharmacological H4R blockade
However, in ME/CFS and dysautonomia, this vital switching mechanism becomes severely impaired, leaving patients unable to generate the rapid ATP required for basic daily activities
Table 1 shows the timepoints when data were obtained from patients in the included studies